Active, not recruitingPhase 1NCT05283109

ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM

Studying Giant cell glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Principal Investigator
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Duke University
Intervention
Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine(biological)
Enrollment
24 enrolled
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05283109 on ClinicalTrials.gov

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Giant cell glioblastoma

← Back to all trials